KR101871133B1 - 벤즈옥사제핀 화합물의 제조 방법 - Google Patents

벤즈옥사제핀 화합물의 제조 방법 Download PDF

Info

Publication number
KR101871133B1
KR101871133B1 KR1020177016062A KR20177016062A KR101871133B1 KR 101871133 B1 KR101871133 B1 KR 101871133B1 KR 1020177016062 A KR1020177016062 A KR 1020177016062A KR 20177016062 A KR20177016062 A KR 20177016062A KR 101871133 B1 KR101871133 B1 KR 101871133B1
Authority
KR
South Korea
Prior art keywords
compound
formula
bromo
reacting
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177016062A
Other languages
English (en)
Korean (ko)
Other versions
KR20170070270A (ko
Inventor
레미 엔젤라우드
다니엘 알 뷰드리
다이앤 이 카레라
수샨트 말호트라
트래비스 레마척
프레데릭 세인트-진
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20170070270A publication Critical patent/KR20170070270A/ko
Application granted granted Critical
Publication of KR101871133B1 publication Critical patent/KR101871133B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177016062A 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법 Expired - Fee Related KR101871133B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024484A Division KR101821468B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016976A Division KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Publications (2)

Publication Number Publication Date
KR20170070270A KR20170070270A (ko) 2017-06-21
KR101871133B1 true KR101871133B1 (ko) 2018-06-25

Family

ID=50241450

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157024484A Expired - Fee Related KR101821468B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020187016976A Withdrawn KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020177016062A Expired - Fee Related KR101871133B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020157024484A Expired - Fee Related KR101821468B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020187016976A Withdrawn KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Country Status (15)

Country Link
US (1) US9303043B2 (enExample)
EP (3) EP2970329A1 (enExample)
JP (6) JP6363120B2 (enExample)
KR (3) KR101821468B1 (enExample)
CN (2) CN105377856B (enExample)
AR (1) AR095365A1 (enExample)
AU (3) AU2014230812B2 (enExample)
BR (1) BR112015020716A2 (enExample)
CA (6) CA2948765A1 (enExample)
IL (1) IL240793A0 (enExample)
MX (1) MX2015011438A (enExample)
NZ (1) NZ711192A (enExample)
RU (2) RU2649976C2 (enExample)
SG (2) SG10201706760YA (enExample)
WO (1) WO2014140073A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201604903VA (en) * 2013-12-16 2016-07-28 Hoffmann La Roche Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
EP4585597A1 (en) 2015-07-02 2025-07-16 F. Hoffmann-La Roche AG Benzoxazepin oxazolidinone compounds and methods of use
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
WO2018021508A1 (ja) * 2016-07-29 2018-02-01 日本たばこ産業株式会社 ピラゾール－アミド化合物の製造方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
SG10201913961PA (en) 2016-12-15 2020-03-30 Hoffmann La Roche Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507577A (ja) 2006-10-23 2010-03-11 エスジーエックス ファーマシューティカルズ、インコーポレイテッド トリアゾロピリダジンタンパク質キナーゼモジュレーター
US20110076292A1 (en) * 2009-09-28 2011-03-31 Nicole Blaquiere Benzoxazepin pi3k inhibitor compounds and methods of use
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
JP4677100B2 (ja) * 1998-10-23 2011-04-27 ダウ・アグロサイエンス・エル・エル・シー ３−（置換フェニル）−５−（置換シクロプロピル）−１，２，４−トリアゾール化合物
BR0211073A (pt) 2001-07-12 2004-12-14 Avecia Ltd Sistema de catalisador, e, processos para a preparação de um catalisador microencapsulado, de bifenilas opcionalmente substituìdas, de alcenos opcionalmente substituìdos, de um produto hidrogenado e de dióis
DE60208815T2 (de) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
KR20090071612A (ko) * 2006-10-23 2009-07-01 에스지엑스 파마슈티컬스, 인코포레이티드 단백질 키나제 조정제로서의 바이시클릭 트리아졸
JP2010516680A (ja) * 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
US8354528B2 (en) * 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
ES2556353T3 (es) * 2008-02-21 2016-01-15 Merck Sharp & Dohme Corp. Compuestos que son inhibidores de las ERK
PL2276767T3 (pl) 2008-03-31 2014-09-30 Genentech Inc Związki benzopiranowe i benzoksepinowe będące inhibitorami pi3k oraz metody ich stosowania
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
RU2557658C2 (ru) * 2009-09-28 2015-07-27 Ф.Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и способы применения
AU2010313469A1 (en) * 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
SG10201706196XA (en) 2012-06-08 2017-08-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507577A (ja) 2006-10-23 2010-03-11 エスジーエックス ファーマシューティカルズ、インコーポレイテッド トリアゾロピリダジンタンパク質キナーゼモジュレーター
US20110076292A1 (en) * 2009-09-28 2011-03-31 Nicole Blaquiere Benzoxazepin pi3k inhibitor compounds and methods of use
JP2013505917A (ja) 2009-09-28 2013-02-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use

Also Published As

Publication number Publication date
AR095365A1 (es) 2015-10-14
CA2897618A1 (en) 2014-09-18
AU2014230812B2 (en) 2016-04-07
SG10201706760YA (en) 2017-10-30
EP3404032C0 (en) 2025-07-02
US9303043B2 (en) 2016-04-05
CA2948765A1 (en) 2014-09-18
KR20150119033A (ko) 2015-10-23
KR20170070270A (ko) 2017-06-21
EP3404032A2 (en) 2018-11-21
WO2014140073A1 (en) 2014-09-18
CN105377856A (zh) 2016-03-02
RU2015138488A (ru) 2017-04-20
IL240793A0 (en) 2015-10-29
JP2018150298A (ja) 2018-09-27
CA2948763C (en) 2018-04-24
EP3404032A3 (en) 2019-03-13
CN105377856B (zh) 2018-05-22
JP2020114814A (ja) 2020-07-30
EP3404032B1 (en) 2025-07-02
AU2018201393A1 (en) 2018-03-15
JP2019089762A (ja) 2019-06-13
RU2649976C2 (ru) 2018-04-06
BR112015020716A2 (pt) 2017-07-18
KR20180070715A (ko) 2018-06-26
JP2018008959A (ja) 2018-01-18
CA3005112A1 (en) 2014-09-18
US20140275523A1 (en) 2014-09-18
AU2016204432A1 (en) 2016-07-21
NZ711192A (en) 2019-04-26
KR101821468B1 (ko) 2018-01-23
JP6363120B2 (ja) 2018-07-25
JP6663459B2 (ja) 2020-03-11
EP3845540A1 (en) 2021-07-07
CN108929333A (zh) 2018-12-04
CA2948763A1 (en) 2014-09-18
AU2014230812A1 (en) 2015-09-03
AU2014230812A8 (en) 2015-09-10
RU2018109979A (ru) 2019-02-28
HK1215433A1 (zh) 2016-08-26
AU2016204432B2 (en) 2017-12-07
SG11201507394RA (en) 2015-10-29
MX2015011438A (es) 2016-02-03
CA3005103A1 (en) 2014-09-18
EP2970329A1 (en) 2016-01-20
CA3005118A1 (en) 2014-09-18
JP2016512209A (ja) 2016-04-25
JP2019031493A (ja) 2019-02-28
JP6442005B2 (ja) 2018-12-19

Similar Documents

Publication Publication Date Title
KR101871133B1 (ko) 벤즈옥사제핀 화합물의 제조 방법
US5252584A (en) Hydroxyquinolone derivatives
EA023045B1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
EP1042317B1 (en) Indole derivatives as PKC-inhiboitors
WO2000078750A1 (en) New pharmaceutically active compounds
AU2020229920A1 (en) Acryloyl-containing nuclear transport regulator and uses thereof
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
NZ614610B2 (en) Heterocyclic compounds for the inhibition of pask
NZ614610A (en) Heterocyclic compounds for the inhibition of pask

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

Not in force date: 20210620

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210620

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000